| Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive studied in …STUDIED_INderived10 of 14show all (up to 200) |
|---|
| → studied in | NCT01746836Phase 2 · recruiting Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib · condition mapped ALIAS · 14 trials mapped (6 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02689440Phase 2 · active not recruiting Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia · condition mapped ALIAS · 14 trials mapped (6 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03459534Phase 3 · recruiting A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs · condition mapped ALIAS · 14 trials mapped (6 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05456191Phase 3 · active not recruiting A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) · condition mapped ALIAS · 14 trials mapped (6 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00254423Phase 2 · completed Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia · condition mapped ALIAS · 14 trials mapped (6 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04070443Phase 2 · active not recruiting Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase · condition mapped ALIAS · 14 trials mapped (6 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04258943Phase 1/Phase 2 · active not recruiting Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia · condition mapped ALIAS · 14 trials mapped (6 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01751425Phase 1 · terminated Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors · condition mapped ALIAS · 14 trials mapped (6 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02311998Phase 1/Phase 2 · completed Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML · condition mapped ALIAS · 14 trials mapped (6 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03885830completed Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients · condition mapped ALIAS · 14 trials mapped (6 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |